COMPANY
Science
Funding and NIH signals
- SEC Form D raise Raised $230.05M (Form D filed Mar 6, 2026). SEC Form D 0001873836-26-000001 (Mar 6, 2026)
Evidence (1 event)
- Mar 6, 2026 · SEC Form D 0001873836-26-000001
Name of Issuer: Science Corp; CIK: 1873836; Address: Alameda, CA; Submission type: D; Filing date: 2026-03-06; Industry Group: Other Technology; Date of First Sale: 2026-02-26; Types of Securities Offered: Equity, Other ("Offering of Series C, Series C-1 and Series C-2 Preferred Stock (collectively, ""Series C""), and the underlying shares of Common Stock issuable upon conversion of Series C."); Business combination transaction: false; Total Offering Amount: 250000000; Total Amount Sold: 230049745; Federal exemptions: 06b
- Mar 6, 2026 · SEC Form D 0001873836-26-000001
Raises and deals from press releases
- Raise Series C · $230M · announced Mar 5, 2026 Company release ↗
Source quote
- Mar 5, 2026 · Company release ↗
“We’ve closed a $230 million Series C financing with participation from Khosla Ventures, Lightspeed Venture Partners, Y Combinator, IQT, and Quiet Capital, all pre-existing investors in Science, among others”
- Mar 5, 2026 · Company release ↗
Timeline
- Trial start Not phased (device or behavioral study): Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration source ↗
- Raise Series C · $230M source ↗
- Trial start Not phased (device or behavioral study): Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD source ↗
- Trial start Not phased (device or behavioral study): PRIMA US-Feasibility Study in Atrophic Dry AMD source ↗
- Trial start Not phased (device or behavioral study): Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration source ↗
Upcoming milestones
- Mar 1, 2029 (ESTIMATED) · Not phased · Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration · NCT07266584
Clinical trials (lead sponsor) 4
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07266584 | Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration | Not phased (device or behavioral study) | Recruiting | Apr 22, 2026 | Mar 1, 2029 (estimated) |
| NCT03392324 | PRIMA US-Feasibility Study in Atrophic Dry AMD | Not phased (device or behavioral study) | Completed | Apr 26, 2018 | May 20, 2026 (actual) |
| NCT04676854 | Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD | Not phased (device or behavioral study) | Active, not recruiting | Nov 24, 2020 | Feb 1, 2024 (actual) |
| NCT03333954 | Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration | Not phased (device or behavioral study) | Completed | Nov 6, 2017 | Dec 12, 2024 (actual) |